Postpartum HemorrhagePhase 4NCT03676621
Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage
A Phase 4 study testing Misoprostol and Oxytocin in people with Postpartum Hemorrhage, run by Assiut University at 1 site in Egypt.
Trial summary
Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall (hysterotomy). This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Postpartum Hemorrhage
- What is being tested?
- Misoprostol and Oxytocin
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 154 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2018to 20 Sep 2021
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- pregnant women
- term pregnancy
- singleton pregnancies
- booked for elective cesarean section
Who cannot join
- • Medical disorders involving the heart,liver,kidney or brain
- Diabetes mellitus and hypertension
- Blood disorders (e.g. coagulopathies , thrombocytopenia )
- Patients requiring blood transfusion due to anemia
- Risk factors for uterine atony e.g. macrosomia , polyhydramnios ,multiple pregnancies
- Placenta previa or placental abruption
Show all 11Show fewer
- Previous major obstetric haemorrhage (>1000ml)in previous deliveries
- Known fibroid or adenomyosis
- Severe preeclampsia
- Uterine anomalies
- Women who received anticoagulant therapy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage :a Randomized Controlled Study
Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall (hysterotomy). This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy
Read the detailed description
patients and methods:
Type of Study
A prospective registered, double blinded, randomized controlled trial
Settings and localizations:
Operative list and emergency unit at Obstetrics and Gynecology Department, Women Health Hospital, Assiut university, Egypt
Preliminary assessment of the patient
Obtain a detailed history from the patient
- Examination of the patient
- General examination and evaluation of the vital signs ofthe patient ( pulse , blood pressure , temperature and respiratory rate)
- Obstetrical examination Ultrasonograghic assessment (fetal viability , number of gestation, placental location, amniotic fluid index) Investigations ( complete blood count, Prothrombin time and concentration). Inclusion criteria: All legally adult pregnant women , above 18 years old ,at term with singleton pregnancies booked for elective caesarean section accepting to participate in the study. Indications of cesarean section: Repeated caesarean section(previous 2 cs or more). previous one caesarean with oligohydramnios. previous one caesarean with contracted pelvis. previous one caesarean with malpresentation. previous one caesarean section with decreased fetal movement. primigravida with malpresentation. primigravida with contracted pelvis. Exclusion criteria: Medical disorders involving the heart,liver,kidney or brain. Diabetes mellitus and hypertension. Patients requiring blood transfusion due to anemia. Risk factors for uterine atony e.g. macrosomia , polyhydramnios ,multiple pregnancies. Placenta previa or placental abruption. Previous major obstetric haemorrhage (>1000ml in previous Deliveries). Known fibroid or adenomyosis. Severe preeclampsia. Uterine anomalies. Women who received anticoagulant therapy. Blood disorders (e.g. coagulopathies , thrombocytopenia). Consent Verbal and written consent were obtained from all eligible women . The candidate women were divided into two groups. A computer generated random numerical table was used by an independent statistician to prepare sealed opaque envelopes containing a group assignment. Two groups of envelopes, corresponding to two study groups, were given to a third party (a nurse), who was unaware of the contents. The nurse distributed envelopes to patients, alternating between the groups. Patientsassigned to group 1 received 5 IU oxytocin IV after delivery of the fetus+ 2 tabs placepo . Patients assigned to group 2 received 400 in the buccal space after anaesthesia + Iv saline infusion Procedure: Cesarean deliveries were performed by well- trained resident doctor supervised by Assistant lecturer or Obstetrician consultant. Cesarean section was performed under spinal anesthesia. Novasoconstrictor was used unless the blood pressure dropped by 20% fromthe baseline value; if this was the case, 10 mg ephedrine was given. Cesarean Delivery technique was the same in all recruited women. Abdominal skin incision was done through a Pfannenstiel incision 2 to 3cm above the symphysis pubis, with the mid portion of the incision within the shaved area of the pubic hair for a length of about 10-12cm was done. After the rectus fascia was opened, the rectus muscles were separated and dissected off the peritoneum which was picked up between two tissue forceps and opened longitudinally. The visceral peritoneum was dissected sharply and gently to separate the bladder from the uterus. The uterus was opened through a transverse lower segment incision. After clamping of the umbilical cord, the women received 1.5 gm Ampicillin -Sulbactam (Ultracillin, Sedico, Egypt) and 80 mg garamycin (Epigent, EPICO, EGYPT) Uterine repair by absorbable continuous vicryl 1 sutures in two layers , parietal peritoneum was sutured by absorbable continuous vicryl sutures, rectus sheath was closed by absorbable continuous vicryl 1. subcutaneous fatty layer was closed by absorbable continuous vicryl 0sutures, skin was closed by vicryl 2-0 by subcuticular sutures. All the towels were weighed before and after cesarean section and the difference were calculated, the amount of intraoperative blood loss was estimated in the suction apparatus in ml. A trained nurse was responsible for blood and amniotic fluid collection during surgery using two separate suction sets, as well as for weighing the surgical towels before and after surgery; all towels that were used were of the same size and weight and every 1 gm increase in weight was equated with 1-mLblood loss. The total amount of intra-operative blood loss was calculated.(blood loss in suction apparatus plus weight difference of used towels Second trained nurse was responsible for post-operative external blood loss measurement during the first 24 hours after surgery by weighing the soaked towels placed in the vulvar area. The post-operative blood loss was calculated (weight difference of towels placed in the vulvar area .The overall blood loss was calculated. Another blood picture was obtained 24 hours postoperative to detect changes in Hb level. The same nurse was responsible for follow up body temperature 2 hours after caesarean section (feverish if temperature is 38ºC or greater) and observation of the patient for nausea , vomiting , chills and diarrhea. Outcomes: Primary outcomes: involved estimation of intraoperative and postoperative blood loss for 24 hours ( blood loss estimation started immediately following the skin incision) Secondary outcomes: Changes in hemoglobin concentration ( hemoglobin concentrations were measured 2 hours before surgery and 24 hours after surgery) Misoprostol-induced maternal adverse effects (postoperativenausea, vomiting, diarrhea, fever and chills . Need to use other uterotonic drugs (oxytocin or ergometrine).Need to do further surgical interventions ( uterine artery ligation ,hysterectomy or re-exploration of the patient) Need for blood transfusion. Sample Size: Sample size was calculated based on the primary outcome (the amount of intraoperative blood loss during cs ) based on the results of previous study ,the mean blood loss with the use of Iv oxytocinas588.9ml with a standerd deviation of 96.3 ml (10). Assuming that buccal misoprostol is more effective in reducing blood loss by 10% 77 participants in each group will have 95% power at significance to detect such a 5% difference women were include in each group taking in account a 10% 77 drop-out rate (Epi-info: centers for disease control and prevention Atlanta, GA) Approval of Ethical Considerations: The Research Ethics Committee of Faculty of Medicine, Assiut University approved the study protocol. Pregnant women who would undergo elective lower segment cesarean section at term ( ≥ 37 weeks) with normal fetal heart tracing received written and verbal information about the study and were asked to participate. Those who agreed signed an informed consent form Statistical Analysis: Data entry and analysis were carried out using Statistical Package of Social Sciences for windows (SPSS, Chicago, Illinois, USA) version 20 Quantitative variables were presented in terms of mean± standard deviation and qualitative variables were expressed as frequency and percentage. Tests of significance (T-test and chi-square) were calculated Significance level was set at P value < 0.05.
- Conditions
- Postpartum Hemorrhage
- Being tested
- Misoprostol, Oxytocin
- Medical subject headings
- Postpartum Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MisoprostolDrug
buccal tablets
OxytocinDrug
intravenous drip
| Study group | Role | What they receive |
|---|---|---|
| study group | Experimental | patients will receive buccal misoprostol Receives: Drug: Misoprostol |
| control group | Active comparator | patients will receive intravenous oxytocin Receives: Drug: Oxytocin |
What is being measured
The primary outcome is the main question the study is designed to answer.
mean blood loss
the amount of blood in towels and suction drain
Measured: 1 hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2018
- Study start1 Nov 2018
- Primary completion30 Aug 2021
- Study completion20 Sep 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postpartum HemorrhageStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 154 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, abo bakr mitwally, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03676621
- Sponsor's protocol ID
- BMISO
- Status last verified
- Sep 2021
- First submitted
- 17 Sep 2018
- Last updated
- 29 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Buccal Misoprostol Versus IV Oxytocin in Prevention of Postpartum Hemorrhage :a Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT03676621
- Acronym / sponsor ID
- BMISO
- Conditions
- Postpartum Hemorrhage
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 154 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Nov 2018 (actual)
- Primary completion
- 30 Aug 2021 (actual)
- Study completion
- 20 Sep 2021 (actual)
- First posted
- 19 Sep 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cesarean delivery is defined as fetal birth through incisions in the abdominal wall and the uterine wall (hysterotomy). This definition does not include removal of the fetus from the abdominal cavity in the case of uterine rupture or in the case of an abdominal pregnancy
Detailed description
patients and methods:
Type of Study
A prospective registered, double blinded, randomized controlled trial
Settings and localizations:
Operative list and emergency unit at Obstetrics and Gynecology Department, Women Health Hospital, Assiut university, Egypt
Preliminary assessment of the patient
Obtain a detailed history from the patient
- Examination of the patient
- General examination and evaluation of the vital signs ofthe patient ( pulse , blood pressure , temperature and respiratory rate)
- Obstetrical examination Ultrasonograghic assessment (fetal viability , number of gestation, placental location, amniotic fluid index) Investigations ( complete blood count, Prothrombin time and concentration). Inclusion criteria: All legally adult pregnant women , above 18 years old ,at term with singleton pregnancies booked for elective caesarean section accepting to participate in the study. Indications of cesarean section: Repeated caesarean section(previous 2 cs or more). previous one caesarean with oligohydramnios. previous one caesarean with contracted pelvis. previous one caesarean with malpresentation. previous one caesarean section with decreased fetal movement. primigravida with malpresentation. primigravida with contracted pelvis. Exclusion criteria: Medical disorders involving the heart,liver,kidney or brain. Diabetes mellitus and hypertension. Patients requiring blood transfusion due to anemia. Risk factors for uterine atony e.g. macrosomia , polyhydramnios ,multiple pregnancies. Placenta previa or placental abruption. Previous major obstetric haemorrhage (>1000ml in previous Deliveries). Known fibroid or adenomyosis. Severe preeclampsia. Uterine anomalies. Women who received anticoagulant therapy. Blood disorders (e.g. coagulopathies , thrombocytopenia). Consent Verbal and written consent were obtained from all eligible women . The candidate women were divided into two groups. A computer generated random numerical table was used by an independent statistician to prepare sealed opaque envelopes containing a group assignment. Two groups of envelopes, corresponding to two study groups, were given to a third party (a nurse), who was unaware of the contents. The nurse distributed envelopes to patients, alternating between the groups. Patientsassigned to group 1 received 5 IU oxytocin IV after delivery of the fetus+ 2 tabs placepo . Patients assigned to group 2 received 400 in the buccal space after anaesthesia + Iv saline infusion Procedure: Cesarean deliveries were performed by well- trained resident doctor supervised by Assistant lecturer or Obstetrician consultant. Cesarean section was performed under spinal anesthesia. Novasoconstrictor was used unless the blood pressure dropped by 20% fromthe baseline value; if this was the case, 10 mg ephedrine was given. Cesarean Delivery technique was the same in all recruited women. Abdominal skin incision was done through a Pfannenstiel incision 2 to 3cm above the symphysis pubis, with the mid portion of the incision within the shaved area of the pubic hair for a length of about 10-12cm was done. After the rectus fascia was opened, the rectus muscles were separated and dissected off the peritoneum which was picked up between two tissue forceps and opened longitudinally. The visceral peritoneum was dissected sharply and gently to separate the bladder from the uterus. The uterus was opened through a transverse lower segment incision. After clamping of the umbilical cord, the women received 1.5 gm Ampicillin -Sulbactam (Ultracillin, Sedico, Egypt) and 80 mg garamycin (Epigent, EPICO, EGYPT) Uterine repair by absorbable continuous vicryl 1 sutures in two layers , parietal peritoneum was sutured by absorbable continuous vicryl sutures, rectus sheath was closed by absorbable continuous vicryl 1. subcutaneous fatty layer was closed by absorbable continuous vicryl 0sutures, skin was closed by vicryl 2-0 by subcuticular sutures. All the towels were weighed before and after cesarean section and the difference were calculated, the amount of intraoperative blood loss was estimated in the suction apparatus in ml. A trained nurse was responsible for blood and amniotic fluid collection during surgery using two separate suction sets, as well as for weighing the surgical towels before and after surgery; all towels that were used were of the same size and weight and every 1 gm increase in weight was equated with 1-mLblood loss. The total amount of intra-operative blood loss was calculated.(blood loss in suction apparatus plus weight difference of used towels Second trained nurse was responsible for post-operative external blood loss measurement during the first 24 hours after surgery by weighing the soaked towels placed in the vulvar area. The post-operative blood loss was calculated (weight difference of towels placed in the vulvar area .The overall blood loss was calculated. Another blood picture was obtained 24 hours postoperative to detect changes in Hb level. The same nurse was responsible for follow up body temperature 2 hours after caesarean section (feverish if temperature is 38ºC or greater) and observation of the patient for nausea , vomiting , chills and diarrhea. Outcomes: Primary outcomes: involved estimation of intraoperative and postoperative blood loss for 24 hours ( blood loss estimation started immediately following the skin incision) Secondary outcomes: Changes in hemoglobin concentration ( hemoglobin concentrations were measured 2 hours before surgery and 24 hours after surgery) Misoprostol-induced maternal adverse effects (postoperativenausea, vomiting, diarrhea, fever and chills . Need to use other uterotonic drugs (oxytocin or ergometrine).Need to do further surgical interventions ( uterine artery ligation ,hysterectomy or re-exploration of the patient) Need for blood transfusion. Sample Size: Sample size was calculated based on the primary outcome (the amount of intraoperative blood loss during cs ) based on the results of previous study ,the mean blood loss with the use of Iv oxytocinas588.9ml with a standerd deviation of 96.3 ml (10). Assuming that buccal misoprostol is more effective in reducing blood loss by 10% 77 participants in each group will have 95% power at significance to detect such a 5% difference women were include in each group taking in account a 10% 77 drop-out rate (Epi-info: centers for disease control and prevention Atlanta, GA) Approval of Ethical Considerations: The Research Ethics Committee of Faculty of Medicine, Assiut University approved the study protocol. Pregnant women who would undergo elective lower segment cesarean section at term ( ≥ 37 weeks) with normal fetal heart tracing received written and verbal information about the study and were asked to participate. Those who agreed signed an informed consent form Statistical Analysis: Data entry and analysis were carried out using Statistical Package of Social Sciences for windows (SPSS, Chicago, Illinois, USA) version 20 Quantitative variables were presented in terms of mean± standard deviation and qualitative variables were expressed as frequency and percentage. Tests of significance (T-test and chi-square) were calculated Significance level was set at P value < 0.05.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| study group | Experimental | Drug: Misoprostolpatients will receive buccal misoprostol |
| control group | Active comparator | Drug: Oxytocinpatients will receive intravenous oxytocin |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- pregnant women
- term pregnancy
- singleton pregnancies
- booked for elective cesarean section
Key exclusion criteria (11 listed)
- • Medical disorders involving the heart,liver,kidney or brain
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Misoprostolbuccal tablets | Drug | study group |
| Oxytocinintravenous drip | Drug | control group |
Primary outcome
mean blood loss
Time frame: 1 hour
the amount of blood in towels and suction drain
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2021.
Related trials for Postpartum Hemorrhage
Not yet recruiting
Comparison of Effect of Two Different Doses of Intravenous Oxytocin on Patients Undergoing Elective Cesarean Section
Postpartum Hemorrhage, Uterine Atony
RecruitingPhase 3
Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk
Postpartum Hemorrhage
Not yet recruitingObservational study
Measured Versus Hemoglobin-Calculated Postpartum Blood Loss in Waterbirth
Postpartum Hemorrhage, Waterbirth
RecruitingObservational study
Long Term Outcome After Use of Vacuum-induced Tamponade for Postpartum Hemorrhage
Postpartum Hemorrhage, Treatment Outcome
RecruitingPhase 2
Prevention of Postpartum Hemorrhage With Tranexamic Acid
Post Partum Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Misoprostol and Oxytocin in people with Postpartum Hemorrhage, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mean blood loss (time frame: 1 hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2021.